Economic evaluation of prescribing conventional and newer oral anticoagulants in older adults

Syed Shahzad Hasan, Chia Siang Kow, Louise E. Curley, Darrin Baines, Zaheer-Ud-Din Babar

Research output: Contribution to journalReview article

Abstract

Introduction: Anticoagulants refer to a variety of agents that inhibit one or more steps in the coagulation cascade. Generally, clinical conditions that require the prescribing of an oral anticoagulant increase in frequency with age. However, a major challenge of anticoagulation use among older patients is that this group of patients also experience the highest bleeding risk. To date, economic evaluation of prescribing of anticoagulants that includes the novel or newer oral anticoagulants (NOACs) in older adults has not been conducted and is warranted. Areas covered: A review of articles that evaluated the cost of prescribing conventional (e.g. vitamin K antagonists) and NOACs (e.g. direct thrombin inhibitors and direct factor Xa inhibitors) in older adults. Expert commentary: While the use of NOACs significantly increases the cost of the initial treatment for thromboembolic disorders, they are still considered cost-effective relative to warfarin since they offer reduced risk of intracranial haemorrhagic events. The optimum anticoagulation with warfarin can be achieved by providing specialised care; clinics managed by pharmacists have been shown to be cost-effective relative to usual care. There are suggestions that genotyping the CYP2C9 and VKORC1 genes is useful for determining a more appropriate initial dose and thereby increasing the effectiveness and safety of warfarin.

LanguageEnglish
Pages371-377
Number of pages7
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Volume18
Issue number4
Early online date9 May 2018
DOIs
Publication statusPublished - 4 Jul 2018

Fingerprint

Anticoagulants
Cost-Benefit Analysis
Warfarin
Costs and Cost Analysis
Antithrombins
Vitamin K
Pharmacists
Health Care Costs
Hemorrhage
Safety
Genes

Cite this

@article{e178e20fc9cb449080ef759dd66e119a,
title = "Economic evaluation of prescribing conventional and newer oral anticoagulants in older adults",
abstract = "Introduction: Anticoagulants refer to a variety of agents that inhibit one or more steps in the coagulation cascade. Generally, clinical conditions that require the prescribing of an oral anticoagulant increase in frequency with age. However, a major challenge of anticoagulation use among older patients is that this group of patients also experience the highest bleeding risk. To date, economic evaluation of prescribing of anticoagulants that includes the novel or newer oral anticoagulants (NOACs) in older adults has not been conducted and is warranted. Areas covered: A review of articles that evaluated the cost of prescribing conventional (e.g. vitamin K antagonists) and NOACs (e.g. direct thrombin inhibitors and direct factor Xa inhibitors) in older adults. Expert commentary: While the use of NOACs significantly increases the cost of the initial treatment for thromboembolic disorders, they are still considered cost-effective relative to warfarin since they offer reduced risk of intracranial haemorrhagic events. The optimum anticoagulation with warfarin can be achieved by providing specialised care; clinics managed by pharmacists have been shown to be cost-effective relative to usual care. There are suggestions that genotyping the CYP2C9 and VKORC1 genes is useful for determining a more appropriate initial dose and thereby increasing the effectiveness and safety of warfarin.",
keywords = "anticoagulants, economic evaluation, older adults, pharmacogenetic, warfarin, Anticoagulants",
author = "Hasan, {Syed Shahzad} and Kow, {Chia Siang} and Curley, {Louise E.} and Darrin Baines and Zaheer-Ud-Din Babar",
year = "2018",
month = "7",
day = "4",
doi = "10.1080/14737167.2018.1474101",
language = "English",
volume = "18",
pages = "371--377",
journal = "Expert Review of Pharmacoeconomics and Outcomes Research",
issn = "1473-7167",
publisher = "Expert Reviews Ltd.",
number = "4",

}

Economic evaluation of prescribing conventional and newer oral anticoagulants in older adults. / Hasan, Syed Shahzad; Kow, Chia Siang; Curley, Louise E.; Baines, Darrin; Babar, Zaheer-Ud-Din.

In: Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 18, No. 4, 04.07.2018, p. 371-377.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Economic evaluation of prescribing conventional and newer oral anticoagulants in older adults

AU - Hasan, Syed Shahzad

AU - Kow, Chia Siang

AU - Curley, Louise E.

AU - Baines, Darrin

AU - Babar, Zaheer-Ud-Din

PY - 2018/7/4

Y1 - 2018/7/4

N2 - Introduction: Anticoagulants refer to a variety of agents that inhibit one or more steps in the coagulation cascade. Generally, clinical conditions that require the prescribing of an oral anticoagulant increase in frequency with age. However, a major challenge of anticoagulation use among older patients is that this group of patients also experience the highest bleeding risk. To date, economic evaluation of prescribing of anticoagulants that includes the novel or newer oral anticoagulants (NOACs) in older adults has not been conducted and is warranted. Areas covered: A review of articles that evaluated the cost of prescribing conventional (e.g. vitamin K antagonists) and NOACs (e.g. direct thrombin inhibitors and direct factor Xa inhibitors) in older adults. Expert commentary: While the use of NOACs significantly increases the cost of the initial treatment for thromboembolic disorders, they are still considered cost-effective relative to warfarin since they offer reduced risk of intracranial haemorrhagic events. The optimum anticoagulation with warfarin can be achieved by providing specialised care; clinics managed by pharmacists have been shown to be cost-effective relative to usual care. There are suggestions that genotyping the CYP2C9 and VKORC1 genes is useful for determining a more appropriate initial dose and thereby increasing the effectiveness and safety of warfarin.

AB - Introduction: Anticoagulants refer to a variety of agents that inhibit one or more steps in the coagulation cascade. Generally, clinical conditions that require the prescribing of an oral anticoagulant increase in frequency with age. However, a major challenge of anticoagulation use among older patients is that this group of patients also experience the highest bleeding risk. To date, economic evaluation of prescribing of anticoagulants that includes the novel or newer oral anticoagulants (NOACs) in older adults has not been conducted and is warranted. Areas covered: A review of articles that evaluated the cost of prescribing conventional (e.g. vitamin K antagonists) and NOACs (e.g. direct thrombin inhibitors and direct factor Xa inhibitors) in older adults. Expert commentary: While the use of NOACs significantly increases the cost of the initial treatment for thromboembolic disorders, they are still considered cost-effective relative to warfarin since they offer reduced risk of intracranial haemorrhagic events. The optimum anticoagulation with warfarin can be achieved by providing specialised care; clinics managed by pharmacists have been shown to be cost-effective relative to usual care. There are suggestions that genotyping the CYP2C9 and VKORC1 genes is useful for determining a more appropriate initial dose and thereby increasing the effectiveness and safety of warfarin.

KW - anticoagulants

KW - economic evaluation

KW - older adults

KW - pharmacogenetic

KW - warfarin

KW - Anticoagulants

UR - http://www.scopus.com/inward/record.url?scp=85050183061&partnerID=8YFLogxK

U2 - 10.1080/14737167.2018.1474101

DO - 10.1080/14737167.2018.1474101

M3 - Review article

VL - 18

SP - 371

EP - 377

JO - Expert Review of Pharmacoeconomics and Outcomes Research

T2 - Expert Review of Pharmacoeconomics and Outcomes Research

JF - Expert Review of Pharmacoeconomics and Outcomes Research

SN - 1473-7167

IS - 4

ER -